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ABSTRACT
Immunotherapy of advanced melanoma with CTLA-4 or PD-1/PD-L1 checkpoint blockade induces in a
proportion of patients long durable responses. In contrast, targeting the MAPK-pathway by selective BRAF
and MEK inhibitors induces high response rates, but most patients relapse. Combining targeted therapy
with immunotherapy is proposed to improve the long-term outcomes of patients. Preclinical data
endorsing this hypothesis are accumulating. Inhibition of the PI3K-Akt-mTOR pathway may be a promising
treatment option to overcome resistance to MAPK inhibition and for additional combination with
immunotherapy.
We therefore evaluated to which extent dual targeting of the MAPK and PI3K-Akt-mTOR pathways
affects tumor immune inﬁltrates and whether it synergizes with PD-1 checkpoint blockade in a BRAFV600E/
PTEN¡/¡-driven melanoma mouse model. Short-term dual BRAF C MEK inhibition enhanced tumor
immune inﬁltration and improved tumor control when combined with PD-1 blockade in a CD8C T cell
dependent manner. Additional PI3K inhibition did not impair tumor control or immune cell inﬁltration and
functionality. Analysis of on-treatment samples from melanoma patients treated with BRAF or BRAF C
MEK inhibitors indicates that inhibitor-mediated T cell inﬁltration occurred in all patients early after
treatment initiation but was less frequent found in on-treatment biopsies beyond day 15.
Our ﬁndings provide a rationale for clinical testing of short-term BRAF C MEK inhibition in combination
with immune checkpoint blockade, currently implemented at our institutes. Additional PI3K inhibition
could be an option for BRAF C MEK inhibitor resistant patients that receive targeted therapy in
combination with immune checkpoint blockade.
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Introduction
Treatment of advanced melanoma has changed dramatically
within the last decade. Immunotherapies that block T cell
checkpoint receptors, such as CTLA-4 and/or PD-1/PD-L1,
and targeted therapies, such as BRAF and MEK inhibitors that
inhibit the activated MAPK pathway in BRAFV600E mutated
melanoma, have shown improved response rates and overall
survival in randomized trials.1-5 The combination of CTLA-4
and PD-1 antibodies, as well as combined targeting of BRAF
and MEK, have further improved patients’ outcome.6-8
Although targeted therapy induces a high number of responses,
the 3-y progression-free survival is approximately only 20% for
patients treated with combined BRAF plus MEK inhibition
(BRAFi C MEKi).9 Combined CTLA-4 plus PD-1 immune
checkpoint blockade shows a plateau at 2-y, with a progres-
sion-free survival of approximately 45–50%.10,11 The character-
istics of the high response rates seen with targeted therapy and
durable responses often seen with immunotherapy provide a
rationale to combine targeted therapy with immunotherapy to
further improve patient survival.12,13 Selective BRAFi have
been shown to induce an activated CD8C T cell inﬁltrate, as
well as increase melanoma MHC expression and melanoma
antigen presentation early-during treatment both in pre-clinical
models and in human melanoma tissue samples.14-20 In mela-
noma mouse models, BRAFi was shown to be synergistic with
adoptive T cell therapy (ACT) in BRAF-driven murine mela-
noma, while its combination with checkpoint inhibitors has
shown limited activity in mice.21-24 Early attempts to combine
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the selective BRAFi vemurafenib with ipilimumab in melanoma
patients failed due to hepatotoxicity.25 Interestingly, Hassel
et al. recently reported the feasibility of combining vemurafenib
and ipilimumab.26
Addition of MEKi to selective BRAFi improved response
rates, progression-free survival and overall survival as compared
to single BRAFi in human melanoma.6,9 The addition of MEKi,
however, raised the concern that it could dampen immune effec-
tor functions.14,27 A recent publication by Hu-Lieskovan et al.
has disproven this concern by showing improved antitumor
activity of anti-PD-1 immunotherapy when combined with
BRAFi C MEKi in a preclinical mouse model of BRAFV600E-
driven melanoma.28 In addition, Ebert et al. recently showed
that in the CT26 mouse colorectal carcinoma model, MEKi
impairs na€ıve CD8C T cell priming, antigen-speciﬁc CD8C T
cell numbers were increased, and that MEKi worked synergisti-
cally with anti-PD-L1 blockade.29 In the same model, Liu et al.
showed that MEKi only transiently inhibits T cell functions and
was synergistic with anti-CTLA-4, anti-PD-1, and anti-PD-L1
blockade.30 In human melanoma, addition of MEKi to BRAFi
did not result in signiﬁcant reduction in immune inﬁltration in
early treatment biopsies.31 These data together provide a clear
rationale for clinical testing of BRAF plus MEK inhibition in
combination with PD-1/PD-L1 blockade.
Activation of the PI3K-Akt-mTOR pathway plays an impor-
tant role in oncogenic transformation and can occur via inacti-
vation of the tumor suppressor protein PTEN.32 Loss of
functional PTEN occurs in up to 30% of melanomas, frequently
in tumors with the BRAFV600E mutation.33,34 PTEN loss has
been associated with reduced response to BRAFi, which can be
overcome by co-targeting the PI3K-Akt-mTOR pathway.35,36
Inhibitors of the PI3K-Akt-mTOR pathway that are clinically
tested are inhibitors of PI3K (PI3Ki, e.g., BKM120) and mTOR
(mTORi, e.g., everolimus).37,38 Combined inhibition of PI3K iso-
forms a, d, and g, but not b, is required to inhibit proliferation
of BRAFV600E/PTENNull-driven murine melanoma.39 In addition,
inhibition of all isoforms by the pan-PI3Ki BKM120 potentiated
the antitumor effect of selective BRAFV600E inhibition.40 Interest-
ingly, a recent study by Peng et al. showed that PTEN loss pro-
motes resistance to T cell-mediated immunotherapy and that
selectively targeting PI3Kb improved the efﬁcacy of immuno-
therapy in BRAFV600E/PTENNull melanoma.41 Inhibition of
mTOR has signiﬁcant antitumor activity in mouse tumor mod-
els and is an approved therapy for several malignancies.38 With
respect to immune modulation, mTOR regulates the differentia-
tion of memory CD8C T cells,42 and leads to improved tumor
control when combined with vaccination in the B16 mouse mel-
anoma model.43 However, mTOR inhibition also increases the
frequency of intratumoral regulatory T cells (Treg) and thereby
limits immune mediated antitumor responses.43-45 These data
indicate that single or dual PI3K-Akt-mTOR pathway targeting
could be an effective combination partner for immune check-
point inhibition,41 but it is unclear so far, which combination
might be most effective. We therefore evaluated to which extent
dual targeting of the MAPK and the PI3K-Akt-mTOR pathways
can improve the outcome of PD-1 blockade in BRAFV600E/
PTEN¡/¡-driven mouse melanoma, and analyzed samples from
melanoma patients treated with BRAFi C/¡ MEKi to gain
insight into optimal combination therapies.
Results
Addition of MEKi to BRAFi results in improved tumor
control and increased tumor lymphocyte inﬁltration
We have previously shown that synchronous BRAFi C MEKi
leads to superior tumor control in an induced BRAFV600E/
PTEN¡/¡ mouse melanoma model as compared to either agent
alone.46 We conﬁrmed this observation in a syngeneic
BRAFV600E/PTEN¡/¡-driven transplantation model.47 We
observed improved tumor control in all combinations of dual
MAPK inhibition and PI3K/mTOR targeting as compared to
single BRAFi (Fig. 1A). When discontinuing the targeted thera-
pies after 14 d of treatment, we observed that addition of
mTORi to BRAFi C MEKi did not improve tumor control.
Although not statistical signiﬁcant, mTORi potentially even
antagonized the effect of BRAFi C MEKi C/¡ PI3Ki (Fig. 1A).
Only the BRAFi C MEKi and BRAFi C MEKi C PI3Ki combi-
nations signiﬁcantly delayed tumor outgrowth as compared to
single BRAFi (Fig. 1B). These observed differences in tumor
outgrowth for the double, triple, and quadruple therapies could
not be explained by a difference in tumor size at treatment
withdrawal, as for example, mTORi combinations induced
equal or even greater tumor size reductions on treatment
(Fig. S1).
To evaluate the different MAPKi and/or PI3K/mTORi
combinations as possible combination partners for check-
point inhibition with anti-PD-1/PD-L1, tumor immune
cell inﬁltration was analyzed by immunohistochemistry
and ﬂow cytometry on 3 d after the start of targeted ther-
apy (Fig. 1C, Table S1 and Fig. S2). Combined BRAFi C
MEKi induced the strongest CD3C T cell inﬁltration
(Fig. 1C and Table S1). Similar patterns were observed by
ﬂow cytometry for the speciﬁc CD4C and CD8C T cell
subsets (Fig. S2). Addition of PI3Ki resulted in less pro-
nounced inﬁltrates, but still signiﬁcantly increased CD3C T
cell counts as compared to untreated mice (p D 0.0159).
Addition of mTORi to BRAFi C MEKi C/¡ PI3Ki induced
less T cell inﬁltration as compared to BRAFi C MEKi, but
this was only signiﬁcant for the BRAFi C MEKi C PI3Ki
C mTORi combination (Fig. 1C). Qualitative analyses by
ﬂow cytometry revealed increased percentages upon tar-
geted therapy for almost all lymphoid populations ana-
lyzed, including Tregs and cancer-associated B cells, while
the frequency of macrophages with a M2-like phenotype
was decreased (Fig. S2).
The proportion of intratumoral IFNg positive CD8C T
cells was highest in tumors from mice treated with MEKi,
BRAFi C MEKi, and BRAFi C MEKi C PI3Ki, while addi-
tion of mTORi reduced this amount (Fig. 1D). Combined
MAPK and/or PI3K/mTOR targeting had no systemic effect
on CD8C T cells as measured by IFNgC CD8C T cells
within the spleen (Fig. S3A). Interestingly, the proportion
of PD-L1-expressing cells within the tumor cell compart-
ment (deﬁned as CD45¡ cells) was decreased upon targeted
therapy (Fig. 1E). The inﬁltrating CD8C T cells expressed
high levels of PD-1 in about 50% of the cells (Fig. 1F), a
marker shown to be associated with tumor-antigen-speciﬁc
T cells,48 and was not altered when targeted agents were
applied. Similarly to the systemic absence of IFNg-
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producing CD8C T cells, few PD-1C CD8C T cells were
found in the spleen and their frequency did not increase
upon targeted therapy (Fig. S3B).
Short-term BRAFi CMEKi shows the strongest synergy
with anti-PD1
The observation that BRAFi C MEKi led to a strong increase of
PD-1C CD8C tumor-inﬁltrating lymphocytes (TILs) raised the
question whether additional PD-1 blockade could induce long-
term tumor control in our model setting. Tumor-bearing mice
were treated with combinations of targeted therapy and anti-PD-
1 checkpoint blockade (Fig. 2A). Identical to Fig. 1, targeted
therapy was withdrawn after 14 d of treatment, while anti-PD-1
was dosed continuously. Single PD-1 blockade did not affect
tumor growth as compared to isotype antibody treated animals
(Figs. 2A and C). Short-term BRAFi C MEKi and BRAFi C
MEKi C PI3Ki showed the strongest synergy with PD-1 block-
ade, resulting in signiﬁcant tumor size reduction at day 32
(Fig. 2B; p < 0.0001 and p D 0.045, respectively). Single BRAFi
or MEKi in combination with PD-1 blockade also reduced
tumor outgrowth as compared to single BRAFi or MEKi alone,
but did not reach statistical signiﬁcance (Fig. 2B). BRAFi con-
taining combinations combined with PD-1 blockade resulted in
complete ongoing responses (CR) in a subset of mice (followed
for up to 200 d, data not shown). This was most frequently
Figure 1. Improved tumor control and lymphocyte inﬁltration by addition of MEKi and PI3Ki to BRAFi. (A) C57BL/6 mice were injected subcutaneously with 3 £ 105
D4M.3A mouse melanoma cells and targeted therapies (14 d) were started after 7 d. BRAFi [B] PLX4720 was provided in chow; MEKi [M] trametinib was dosed by daily
oral gavage at 15 mg (on average 0.75 mg/kg); PI3Ki [P] BKM120 daily oral gavage at 400 mg (on average 20 mg/kg); and mTORi [mT] everolimus daily oral gavage at
100 mg (on average 5 mg/kg). Shown are tumor growth curves from mice treated with the indicated combinations (mean § SEM and n D 9–11). (B) Mean tumor size §
SD at day 28 (no mice removed from experiments) is depicted in a dot plot (Mann–Whitney U-test). (C) D4M.3A tumor-bearing C57BL/6 mice (each group n D 5) were
treated for 3 d with MAPK and/or PI3K pathway inhibitors, and tumors were analyzed by immunohistochemistry for CD3C cell inﬁltration and analyzed by ﬂow cytometry
for (D) proportion of IFNg producing CD8C T cells; (E) PD-L1 expression of CD45¡ cells; and (F) expression of PD-1 on CD8C T cells.
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observed in the BRAFi C MEKi C anti-PD-1 combination
(Fig. 2C, 4/9 CRs). Rechallenge of mice that had achieved a com-
plete response with the same tumor cell line did not result in
tumor outgrowth in the majority of mice (data not shown).
Tumor control upon targeted therapy plus PD-1 blockade
did not correlate with altered tumor T cell inﬁltration or
changes in T cell function. Speciﬁcally, the addition of anti-
PD-1 therapy did not increase the number of inﬁltrating
Figure 2. BRAFi C MEKi has the strongest short-term synergy with anti-PD1. (A) Tumor-bearing mice were treated as described in Fig. 1 with the indicated small mole-
cules targeting MAPK and/or PI3K pathway for 14 d and concurrently either with anti-PD-1 or isotype mAb (twice weekly 100 mg intraperitoneal). Anti-PD-1 or control
antibody was continued beyond day 14. Shown are the tumor sizes of the different treatment groups (mean § SEM and n D 8–10). (B) Tumor sizes from 2A at day 32 are
depicted in a dot plot (mean § SD) and statistical signiﬁcance is analyzed comparing isotype versus anti-PD1 treatment (Mann–Whitney U-test). (C) Individual tumor
growth curves of mice are plotted per condition and the average of the group is indicated by a bold line.
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CD3C T cells as compared to targeted therapy (Figs. 3A and B
and Table S2). Addition of anti-PD-1 did not alter the IFNgC
CD8C T cell proportion, the granzyme BC CD8C T cell
proportion, or the proportion of CD44hi CD62Llo CD8C
T cells within the tumors, except for granzyme-positive CD8C
T cells in combination with BRAFi (Figs. 3C–E).
Figure 3. Addition of anti-PD1 to MAPK and PI3K pathway inhibition does not alter the inﬁltration and activation/effector status of CTLs. (A) Tumors from mice treated as
described in Fig. 2A (n D 4–5 per group) were analyzed by immunohistochemistry for CD3 inﬁltration on day 3. The black scale bars equal 3 mm and the high magniﬁca-
tion inserts are 400 mm squared. Quantiﬁcation depicted in (B) In the same setup as A and B, tumors were digested and analyzed by ﬂow cytometry for the percentages
of (C) IFNg producing CD8C T cells (D) granzyme B producing CD8C T cells; and (E) CD44highCD62Llow expressing CD8C T cells.
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Synergy of targeted therapy with anti-PD-1 is dependent
on the presence of CD8C T cells
The near equal synergy in tumor control with BRAFi C MEKi
C PI3Ki C anti-PD-1 as compared to BRAFi C MEKi C anti-
PD-1 (Fig. 2) and the absence of changes in tumor T cell inﬁl-
trates upon addition of anti-PD-1 (Fig. 3), raised the question
whether targeted therapy-induced CD8C T cell inﬁltration is
the major mechanism for synergy with PD-1 blockade. To
address this question, we depleted CD4C or CD8C T cells in
parallel with BRAFi CMEKi C anti-PD-1 treatment. Depletion
of CD8C cells, but not CD4C cells, completely abolished the
control of tumor outgrowth observed upon BRAFi C MEKi C
anti-PD-1 (Figs. 4A and B) and almost completely abolished
the induction of complete responders (Fig. S4A and B).
Remarkably, depletion of CD8C cells did not result in a signiﬁ-
cantly faster outgrowth after BRAFi CMEKi treatment as com-
pared to isotype depletion (Fig. S4B). This might indicate that
the initial tumor control is dominated by the targeted therapy
and that the observed CD8C T cell inﬁltration is required for
anti-PD-1-mediated tumor control (Fig. 1A and Fig. 4B). Inter-
estingly, depletion of CD4C T cells had a minor positive effect
on tumor outgrowth control upon BRAFi C MEKi C anti-PD-
1 (Fig. 4A), which was preceded by a statistically signiﬁcant dif-
ference in tumor size at the moment targeted therapy was
halted (Fig. S4B; pD 0.0002). This might result from interfering
with intratumoral CD4C regulatory T cells (Tregs), which were
increased upon BRAFi C MEKi, but not on single agent BRAFi
(Fig. S2H).
MAPKi induces transient CD8C T cell inﬁltration
Our rationale to combine short-term targeted therapies C/¡
anti-PD-1 is based on the observations of high T cell inﬁltration
occurring early during treatment, which disappeared at disease
progression.17,20,21,49 To investigate the kinetics of immune
inﬁltration upon targeted therapy, we treated tumor-bearing
mice with BRAFi or BRAFi C MEKi.6,9 The amount of tumor-
inﬁltrating lymphocytes was analyzed by immunohistochemis-
try at different time points. An increase of CD3C T cell inﬁl-
trates was found in both treatment groups, starting already on
day 3 (Figs. 5A–C). Decreased T cell inﬁltration was observed
upon BRAFi on day 28 (Fig. 5A, upper row, and Fig. 5B p D
0.0635 compared to day 14), which was concurrent with tumor
progression (Fig. S5). In contrast, BRAFi C MEKi induced
incremental T cell inﬁltration at all-time points analyzed
(Fig. 5A lower row, and Fig. 5C). Moreover, this increase of
tumor inﬁltrates was also accompanied by continuous tumor
control by BRAFi CMEKi (Figs. S5A–D). Our effort to identify
the optimal treatment duration by simulation in our mouse
model was thus hampered by the insufﬁcient tumor control
with BRAFi and the incremental tumor control upon BRAFi C
MEKi.
We therefore analyzed CD8C T cell inﬁltration in paired
pre- and on-treatment human melanoma biopsies from
patients responding to BRAFi or BRAFi C MEKi. We selected
patients that showed partial responses evaluated by RECIST 1.1
and had undergone on-treatment biopsy during on-going
responses, thus not at disease progression. In early biopsies
(<15 d of treatment) of BRAFi and BRAFi C MEKi treated
patients, we found increased CD8C T cell inﬁltrates as com-
pared to the baseline T cell inﬁltrates (Figs. 5D and E left;
shown is fold increase as compared to pre-treatment samples;
BRAFi: median 7 d, range 2–13 d; BRAFi CMEKi: median 7 d,
range 4–15 d on treatment). However, in the majority BRAFi
treated patients (5/7 patients) the amount of CD8C T cell inﬁl-
trates was reduced as compared to pretreatment levels, when
the biopsies were taken beyond 15 d (Fig. 5D, right; median
242 d, range 27–365 d on treatment). In contrast, 2/4 treatment
biopsies from BRAFi C MEKi treated patients biopsied beyond
15 d maintained an increased level of CD8C T cell as compared
to pre-treatment (Fig. 5E, right; median 227 d, range 34–497 d
on treatment).
Discussion
Combining targeted therapy and immunotherapy to potentiate
improved long-term patients’ outcome was proposed soon after
they were established as systemic therapies for advanced mela-
noma.12,20,50 Unfortunately, toxicities have been observed for
the combination of the BRAFi vemurafenib with anti-CTLA-4
Figure 4. Synergy of targeted therapy with anti-PD-1 is dependent on the presence of CD8C T cells. (A) Tumor growth curves of D4M.3A tumor-bearing C57BL/6 mice
treated for 14 d with BRAFi and MEKi combined with isotype or anti-PD-1 as described in Fig. 2A. In addition, mice were treated with twice weekly intraperitoneal isotype
mAb, anti-CD4C or anti-CD8C depleting antibodies at 250 mg (mean§ SEM and nD 8–9). (B) Tumor size and mean§ SD at day 28 is depicted in a dot plot (Mann–Whit-
ney U-test).
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immune checkpoint blockade,25,51 leading to suspension of
these trials. PD-1 blockade has been shown in large randomized
trials to induce less grade 3/4 toxicities, while inducing higher
response rates as compared to ipilimumab,7,52 making PD-1/
PD-L1 inhibitors possibly a more safe combination partner for
targeted therapies. Recent preclinical work has indicated
Figure 5. Transient inﬁltration of T cells upon MAPK pathway inhibition. D4M.3A tumor-bearing C57BL/6 mice were treated with BRAFi and/or MEKi. (A) Tumors treated
for the respective time were analyzed by immunohistochemistry for CD3C cell inﬁltration. Representative immunohistochemistry stainings are shown. The black scale
bars equal 3 mm and the high magniﬁcation inserts are 400 mm squared. (B, C) Automated software quantiﬁcations for the proportion of inﬁltrating CD3C cells are
depicted as a fraction of total nuclei (mean indicated by horizontal line). (D, E) Intrapatient pre- and during treatment tumor biopsies from humane melanoma treated
with either BRAFi or BRAFi C MEKi. Samples were analyzed by immunohistochemistry for CD8C cell inﬁltration in a blinded manner. The average CD8C cell count per
HPF is plotted and median is indicated by horizontal red line. Patient samples were grouped as early on treatment biopsies (< 15 d of treatment) and late on treatment
biopsies (> 15 d).
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synergistic effects of synchronous BRAFi and ACT.24 The
observation that BRAFi C MEKi alleviates some BRAFi-
induced toxicities,46,53 provides another argument for combin-
ing BRAFi C MEKi with immune checkpoint blockade. How-
ever, this raised a concern about possible impairment of T cells
functions upon MEKi.27 Recent in vivo studies have reported
synergy between MEKi and PD-L1 blockade, and BRAFi C
MEKi and PD-1 blockade,28-30 showing that the previously
described detrimental effects from MEKi on na€ıve T cells,27
may not be relevant to intratumoral CD8C effector T cells.
Indeed, in patients receiving BRAFi CMEKi it has been shown
that numbers of tumor inﬁltrating CD8C T cells were increased
after start of treatment.30 Furthermore, increased intratumoral
CD8C T cell numbers have been associated with improved out-
come upon PD-1 blockade.54 Based on these data, several trials
testing continuous BRAFi CMEKi in combination with PD-L1
or PD-1 blockade have been initiated (NCT02027961 and
NCT01656642).
We have aimed to analyze the effect of single and dual
MAPK pathway inhibition in combination with additional sin-
gle or dual PI3K-Akt-mTOR pathway inhibition and its poten-
tial synergy with PD-1 blockade. Additional PI3K-Akt-mTOR
pathway targeting might be an interesting option for patients
unresponsive to BRAFi C MEKi. This urged the preclinical
investigation of pan-PI3K and mTOR inhibitors for their
assumed T cell inhibitory function.55
We found that short-term MAPK pathway inhibition
induced strong tumor control and enhanced tumor immune
inﬁltration as compared to untreated mice or single BRAFi
treated mice. This is in line with preclinical and clinical obser-
vations showing increased tumor control and T cell inﬁltration
upon dual MAPK-targeted therapies.6,28,53,56,57
Previous data showed that additional blockade of PI3Ka,
PI3Kd, and PI3Kg slightly improved tumor control and pre-
vented resistance upon MEKi in BRAFV600E/PTENNull mela-
noma.39 In our experiments testing different targeted therapy
combinations, we found no signiﬁcant additional tumor reduc-
tion of short-term pan-PI3K inhibition by BKM120 in addition
to BRAFi and BRAFi C MEKi. Furthermore, administration of
BKM120 in combination with BRAFi C MEKi did not signiﬁ-
cantly alter T cell inﬁltration and effector function. This seems
contradictory to the result by Peng et al., who showed that pan-
PI3Ki interferes with T cell activation in a vaccination model.41
However, similar to MEKi,29 pan-PI3Ki might predominantly
alter early T cell activation, while to a lesser extent the intratu-
moral effector T cell function.
Additional mTOR targeting by everolimus with BRAFi C
MEKi or BRAFi CMEKi C PI3Ki resulted in loss of the signiﬁ-
cantly improved tumor control upon BRAFi C MEKi C/¡
PI3Ki. This is in contrast to previous in vitro,35,58 and in vivo
studies where mTORi has been shown to improve antitumor
immune responses.59,60 Addition of mTORi to BRAFi C MEKi
C/¡ PI3Ki also reduced the tumor inﬁltration of CD3C lym-
phocytes and IFNg-producing effector CD8C T cells. Combina-
tions with mTORi were therefore not further tested in
combination with PD-1 blockade in our work here.
It was previously shown that increased intratumoral CD8C
T cell inﬁltration upon BRAFi C/¡ MEKi is associated with
improved outcome with PD-1 blockade in mice.28 In patients,
increased CD8C T cell tumor inﬁltration was associated with
better outcome upon PD-1 blockade.54 Therefore, we have
addressed the effect of adding anti-PD-1 treatment to targeted
therapy on tumor outgrowth. Indeed, concurrent with
increased inﬁltration of TILs, we observed synergistic effects of
the addition of anti-PD-1 to targeted therapy, most strongly in
the combination of BRAFi C MEKi. We regularly observed
complete responses for all targeted therapies where anti-PD-1
was added, with the exception of the MEKi group. This indi-
cates that early full eradication of the tumors depends mainly
on BRAFi C anti-PD-1 combination. However, the addition of
MEKi still has an effect on tumor outgrowth in non-complete
responders. In that way, addition of MEKi to BRAFi C PD-1
blockade is beneﬁcial for the whole cohort. We found that addi-
tion of pan-PI3Ki did not inﬂuence the synergy of BRAFi C
MEKi with PD-1 blockade. Furthermore, the addition of short-
term pan-PI3Ki did not inhibit CD8C T cell functionality,
which seems to be in contrast to Peng et al., who showed that
selective PI3Kb inhibition improved the efﬁcacy of anti–PD-1
checkpoint blockade in an induced BRAFV600E/PTENNull
mouse melanoma model.41
Our data suggest that adding pan-PI3Ki in patients that
respond to BRAFi C MEKi has no beneﬁt on tumor control.
However, our observation that adding pan-PI3Ki to BRAFi C
MEKiC anti-PD-1 does not hamper synergistic effects provides
a rationale to test pan-PI3K inhibitors in combination with
immunotherapy in patients being resistant to BRAFiCMEKi.
Depletion of CD8C cells completely abolished the synergis-
tic effect of BRAFi C MEKi in combination with anti-PD-1.
This conﬁrmed the dogma that the mechanism of anti-PD-1
therapy is at least in part mediated through CD8C T cells.61,62
Although an increase in IFNg producing CD8C T cells was
observed upon targeted therapy, we could not ﬁnd a change
in activation markers on bulk CD8C T cells with the addition
of anti-PD-1. Interestingly, we observed rejection of tumor
cells when injected in mice that had a previous complete
response. This indicates that an immunological memory
response is induced upon the combination therapy. Since the
nature of this model did not allow us to follow tumor speciﬁc
T cell clones, we do not know which percentage of effector
cells contributed to the response. Kvistborg et al. have shown
that tumor-speciﬁc T cell populations with a very low fre-
quency can be found in patients treated with anti-CTLA-4.63
This might suggest that only a limited proportion of inﬁltrat-
ing T cells is actually exhibiting antitumor speciﬁcity. It is of
interest to further study the antitumor speciﬁcity of the inﬁl-
trating lymphocytes and elucidate the proportion that is
responsible for tumor control in the complete responders.
Even though the window for improvement is limited, deple-
tion of CD4C T cells had a beneﬁcial effect on early tumor
control. Mice that were treated with BRAFi C MEKi C anti-
PD-1 in the absence of CD4C T cells had signiﬁcantly smaller
tumors at the moment targeted therapy was halted. A likely
explanation for this observation could be that Tregs have an
important immunosuppressive function on tumor speciﬁc T
cells. Indeed, we found that about 60% of CD4C positive T
cells in untreated D4M.3A tumors are positive for FoxP3 and
this proportion slightly increased upon BRAFi C MEKi, but
not upon BRAFi.
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In addition to Tregs, other immune regulatory cells, like
monocytes, tumor associated B cells, neutrophils, and macro-
phages were present in this model. No clear correlations were
observed between these populations and the synergistic effect
of combined targeted therapy and anti-PD-1. However, this
does not exclude that depletion of, e.g., Treg, tumor-associated
macrophages, neutrophils, or cancer-associated B cells in addi-
tion to BRAFi C MEKi C/¡ PI3Ki might further improve
long-term outcome.
In contrast to the work of Hu-Lieskovan et al., we did not
apply continuous and concomitant targeted therapy. The ratio-
nal for this decision was based on our observation of a patient
achieving long-term tumor control after receiving short term
BRAFi C MEKi subsequent to PD-1 blockade (Blank et al.,
unpublished), and from another case report of long-term
BRAFi being counterproductive for increasing the intratumoral
T cell response.21 Indeed, we were able to observe long-term
complete responses in the D4M.3A mouse melanoma model,
when applying short-term targeted therapy. This has not been
described in preclinical work using another subcutaneous
mouse melanoma model (harboring BRAFV600E and CDKN2
mutations) testing continuous application of BRAFi CMEKi.24
However, these observed differences could also be due to the
different genetic driver mutations present in these cell lines.24,47
Testing continuous and intermittent application of BRAFi C
MEKi in combination with PD-1 blockade in the latter model
could address this question. On the other hand, we found that
inﬁltration of T cells was already prevalent within the ﬁrst week
after start of treatment, both in mouse and human melanoma.
This supports previous ideas that the induction of a favorable
antitumor microenvironment occurs early after targeted ther-
apy initiation and might disappear on treatment.20,21,31 In this
way, current clinical study designs of long BRAFi C MEKi
induction phases before PD-1/PD-L1 blockade might under-
mine an improved antitumor immune response. This idea is
further supported by recent ﬁndings, that MAPKi induces an
innate anti-PD-1 resistance (IPRES) signature in melanomas,
which was found in patients not responding to PD-1
blockade.64
Our results are limited by preclinical mouse modeling and
limited availability of human tumor samples. Validation of
these results in clinical trials is warranted. Several clinical trials
are studying combinations of dual MAPK-pathway inhibition
(dabrafenib C trametinib or vemurafenib C cobimetinib) and
immune checkpoint blockade (e.g., anti-CTLA-4 or anti-PD-1/
PD-L1) in melanoma patients (NCT01940809; NCT01656642;
NCT02027961; NCT02130466; NCT02224781). However,
none of these trials addresses the question of what the optimal
dosing schedule of targeted therapy should be in order to
achieve the optimal outcomes for patients. Our data suggest
that combining short-term MAPK-pathway C/¡ PI3K-path-
way inhibition with immunotherapies improves antitumor
immune responses, and may be superior to continuous combi-
nation therapy. Based on our results, we have initiated two
phase 2 studies; one study in advanced melanoma comparing
the combination of anti-PD-L1 (pembrolizumab) with two dif-
ferent intermittent BRAFi C MEKi (dabrafenib C trametinib)
schemes versus continuous BRAFi C MEKi (IMPemBra,
NCT02625337) and one neoadjuvant study exploring a short-
term induction phase of BRAFi C MEKi followed by anti-PD1
versus continuous triple therapy in resectable stage 3 or 4 mela-
noma (NCT02858921).
Materials and methods
Syngeneic mouse melanoma model
D4M.3A cells were generated from Tyr::CreER;BrafCA;Ptenlox/lox
mice by Jenkins et al.47 and kindly provided to us. The cells
were cultured in DMEM/F-12 advanced media (Life Technolo-
gies) with 5% FBS, 1£ penicillin/streptomycin (Sigma-Aldrich),
and 1£ glutamine and resuspended in PBS C matrigel (BD
Biosciences) before subcutaneous injection (3 £ 105 cells) in
male C57BL/6 mice (Charles River and Janvier). Tumor out-
growth was followed by two-dimensional digital caliper meas-
urements of the greatest longitudinal diameter (length) and the
greatest transverse diameter (width). Tumor volume based on
caliper measurements was calculated by the modiﬁed ellipsoidal
formula. Tumor volume D 1/2 (length £ width2). Average
tumor sizes are plotted as long as at least 50% of the animals
within a group were alive. The last measured tumor size of
mice that reached the experimental end point was taken along
for the subsequent time points for calculating group averages.
All described animal experiments were approved by the Animal
Experimentation Committee of the Netherlands Cancer Insti-
tute. Mice were treated in accordance with the Dutch law on
animal experimentation.
Treatment of tumor-bearing mice
PLX4720, a research analog of the selective BRAF inhibitor
vemurafenib (PLX4032) (provided by Plexxikon) was used in
chow.65 At the start of the experiments, the mice were switched
either to a chow diet containing 417 mg/kg PLX4720 or to con-
trol chow containing no compound. On average the food dos-
ing is similar to a daily 50 mg/kg dosing by oral gavage.65 The
MEK inhibitor trametinib (Selleckchem) was dissolved in 0.5%
hydroxypropyl methylcellulose and 0.2% Tween-80 (Sigma-
Aldrich) and was administered daily by oral gavage of 15 mg
(on average 0.75 mg/kg), once daily, 5 d per week for the indi-
cated durations. The pan-PI3K inhibitor BKM120 (provided by
Novartis) was dissolved in 0.5% methylcellulose and 0.5%
Tween-80, and 400 mg (on average 20 mg/kg), once daily, 5 d
per week. The mTOR inhibitor everolimus (provided by
Novartis), diluted in 5% glucose, was administered by daily oral
gavage at 100 mg (on average 5 mg/kg), once daily, 5 d per
week for the indicated durations. Anti-PD-1 (clone RMP1-14,
BioXcell) was injected intraperitoneal twice weekly 100 mg
mAb for the complete duration of the experiments. Control
mice, not receiving the anti-PD-1 antibody, were administered
with the appropriate isotype control (Rat IgG2a, clone 2A3,
BioXcell) at the same dose.
Flow cytometric analysis of immune populations
Tissues were removed from the animals directly after euthana-
sia. Single-cell suspensions from the tissues were obtained by
disruption of the tissue by slicing of the material followed by a
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1 h digestion in digestion medium at 37C. Digestion medium
contained 2 mg/mL collagenase A (Sigma-Aldrich) and 1 mg/
mL DNAse (Sigma-Aldrich). After digestion the suspension
was ﬁltered through a 70 mm ﬁlter (BD Biosciences) to get rid
of debris. The obtained single-cell suspension was then stained
with ﬂuorochrome labeled antibodies and analyzed for expres-
sion using a LSR Fortessa (BD Biosciences) and FlowJo soft-
ware (Tree Star Inc.). Intracellular staining was performed
using the Intracellular Fixation & Permeabilization Buffer Set
from eBioscience according to the manufacturers’ protocol.
Lymphocyte panel; CD45.2-PE-Cy7 (1:200; clone 104, BD
Biosciences), CD11b-Alexa Fluor 700 (1:200; clone M1/70,
eBioscience), CD19-PE-Cy5.5 (1:400; clone 1D3, eBioscience),
NK1.1-APC (1:100; clone PD136, eBioscience), CD3-PE-
eFluor610 (1:200; clone 145-2C11, eBioscience), CD4C-APC-
H7 (1:200; clone GK 1.5 BD Biosciences), CD8C-V500 (1:200;
clone 53–6.7, BD Biosciences), PD-L1-PE (1:200; clone MIH5,
eBioscience), PD-1-FITC (1:100; clone J43, eBioscience), DAPI
(1:20).
Myeloid panel; CD45.2-PE-Cy7 (1:200; clone 104, BD Bio-
sciences), CD11b-FITC (1:200; clone M1/70, eBioscience),
CD11c-PB (1:400; clone N418, Biolegend), F4/80-APC-
eFluor780 (1:200; clone BM8, eBioscience), Ly6G-APC (1:400;
clone 1A8, BD Bioscience), Ly6C-PE (1:800; clone HK1.4, eBio-
science), MHC-II-PerCp-eFluor710 (1:200; clone M5/114.15.2,
eBioscience), LIVE/DEAD405 Fixable Aqua Stain, 1:100 in
FACS buffer (Invitrogen).
Intracellular panel; CD45.2-PE-Cy7 (1:200; clone 104, BD
Biosciences), CD11b-Alexa Fluor 700 (1:200; clone M1/70,
eBioscience), CD3-PE-eFluor610 (1:200; clone 145-2C11, eBio-
science), CD4C-APC-H7 (1:200; clone GK 1.5 BD Biosciences),
CD8C-PerCP-eFluor710 (1:400; clone 53–6.7 eBioscience),
FoxP3-APC (1:100; clone FJK-16s, eBioscience), IFNg-
eFluor450 (1:200; clone XMG1.2, eBioscience), CD44-FITC
(1:200; clone IM7, eBioscience) CD62L-Alexa Fluor 700 (1:200;
clone MEL-14, eBioscience), granzyme B (1:200; clone CLB-
GB11, Sanquin), LIVE/DEAD405 Fixable Aqua Stain, 1:100 in
FACS buffer (Invitrogen).
Prior to intracellular staining, cells were incubated in IMDM
medium containing 8% FCS C Pen/strep C b-mercaptoethanol
for 3 h in the presence of 1 mL/mL golgiplug (BD Biosciences).
For the analysis of IFNg, cells were stimulated with PMA
(50 ng/mL, Sigma-Aldrich) and Ionomycin (1 mM, Sigma-
Aldrich).
Depletion experiments
For depletion of CD4C and CD8C T lymphocytes mice were
peritoneal injected twice weekly with 250 mg of anti-CD4C
(clone GK1.5, BioXcell) and/or anti-CD8C (clone 2.43, Bio-
Xcell) antibodies, respectively. Control mice were injected with
Rat IgG2b isotype control (clone LTF-2, BioXcell). Depletion of
the speciﬁc populations was conﬁrmed by ﬂow cytometry at
day 26 after start of the experiment.
Histological analysis and immunohistochemistry
Tissues were removed from the mice directly after euthanasia.
They were ﬁxed in formalin and embedded in parafﬁn. 4 mm-
thick sections were made and stained with anti-CD3 (clone
RM-9107, Thermo Scientiﬁc) according to standard proce-
dures. CD3 inﬁltration was scored using SlidePath Tissue
Image Analysis software (Leica Microsytems). Human forma-
lin-ﬁxed parafﬁn-embedded tumor samples were cut into
4 mm-thick sections and stained with anti-CD8C (clone C8/
144B, DAKO) by standard procedures. Slides were scored by
counting positive cells in 3–4 random high-power ﬁelds (HPF).
Patient material
Melanoma biopsies from patients treated at the Melanoma
Institute Australia Sydney and the Netherlands Cancer Institute
were taken from patients prior to commencing either vemura-
fenib (960 mg orally twice daily) or dabrafenib (150 mg orally,
twice daily) alone, or dabrafenib combined with trametinib
(2 mg orally daily), early during treatment (<15 d, EDT) or
late during treatment (> 15 d, LDT). Biopsies were performed
under the Treat Excise Analyze for Melanoma (TEAM) proto-
col,20,49 or the N03LAM protocol (NKI material collection
trial). Both protocols were approved by the local human
research ethics committees and informed consent from the
patients was obtained before inclusion in the analyses.
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